NL-OMON34111尚未招募不适用
The role of PPAR-* in familial partial lipodystrophy - PPAR-y and FPLD
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1.PPAR-* mutation
- •2.Medical ground for treatment with PPAR-* agonists
- •3.Given informed consent
- •Healthy controls
- •1.Matched to cases for BMI, age and gender
- •2.Given informed consent
- •Patients with type II diabetes
- •1.Matched to cases for BMI, age and gender
- •2.On insulin therapy
- •3.Given informed consent
排除标准
- •1.current use of PAPR-y agonist
- •2.known adverse reactions to PPAR-* agonists
- •1.Current use of the following medications: Heparin, or other blood diluting medication
- •2.Hepatic dysfunction
- •3.End stage renal disease
- •4.Pregnancy
- •5.History of bleeding or recent surgical intervention
- •6.Any other condition that in the opinion of the investigator would make the subject not eligible for participation in the trial
研究者
相似试验
尚未招募
不适用
the Prevalence of Familial Partial Lipodystrophy in patients with extreme insulin-resistant type 2 Diabetesabnormal distribution of subcutanous fatlipodystrophy1002742410018424NL-OMON32201Academisch Medisch Centrum90
已完成
不适用
Study of Cortisol Metabolism in Familial Partial Lipodystrophy Type 2Familial Partial Lipodystrophy Type 2NCT04845165University Hospital, Lille25
已完成
不适用
Insulin Regulated Amino Peptidase in Patients With Familial Lipodystrophy of DUNNIGANLipodystrophyInsulin ResistanceNCT04578379Centre Hospitalier Universitaire de la Réunion70
已完成
4 期
Regulation of Lipoprotein Transport in Metabolic SyndromeLipid DisordersObesityCardiovascular DiseaseNCT00841217The University of Western Australia13
招募中
不适用
Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)LipodystrophyNCT05996536National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)14